VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Inserm · Université Paris Cité · +3 more institutions
Abstract
Multitarget antiangiogenic tyrosine kinase inhibitors (TKI) have been shown to reduce regulatory T cells (Treg) in tumor-bearing animals and patients with metastatic renal carcinomas. However, a direct role of the VEGF-A/VEGFR pathway inhibition in this phenomenon is a matter of debate and molecular mechanisms leading to Treg modulation in this setting have not been explored to date. Treg proportion, number, and proliferation were analyzed by flow cytometry in peripheral blood of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab, a monoclonal antibody targeting specifically VEGF-A, and in colon cancer-bearing mice (CT26) treated with drugs targeting the VEGF/VEGFR axis. The direct…
Citation impact
- FWCI
- 11.25
- Percentile
- 100%
- References
- 53
Authors
10- MTMagali TermeCorresponding
Inserm, Université Paris Cité, Sorbonne Paris Cité, Hôpital Européen Georges-Pompidou, Paris Cardiovascular Research Center
- SPSimon Pernot
Inserm, Université Paris Cité, Sorbonne Paris Cité, Hôpital Européen Georges-Pompidou, Paris Cardiovascular Research Center
- EMElie Marcheteau
Inserm, Université Paris Cité, Sorbonne Paris Cité, Hôpital Européen Georges-Pompidou, Paris Cardiovascular Research Center
- FSFederico Sandoval
Inserm, Université Paris Cité, Sorbonne Paris Cité, Hôpital Européen Georges-Pompidou, Paris Cardiovascular Research Center
- NBNadine Benhamouda
Inserm, Université Paris Cité, Sorbonne Paris Cité, Hôpital Européen Georges-Pompidou, Paris Cardiovascular Research Center
Topics & keywords
- Blockade
- Cancer research
- Medicine
- Colorectal cancer
- Bevacizumab
- Cancer
- Immunology
- Internal medicine
- Good health and well-being